Nucleosyn
  • Home
  • Products
    • All products
    • Products categories
    • DNA-RNA
    • Synthetic lipids
    • Stable isotope
    • Custom chemical synthesis
  • Capabilities
  • About Us
  • Contact
  • Linkedin

My selection

Stable isotope

Nucleosyn provides Custom Stable Isotope (2H, 13C, 15N) compounds to support projects dedicated to : Bioanalytics, Omics research, Molecular Imaging, and Biomarker discovery.

[13CD3]-Sorafenib

CAS #
1210608-86-8
Packing size
5mg, 10mg, 25mg, bulk
Anticancer drugTherapeutic Drug Monitoring (TDM)SIL
-Sorafenib Image 1

Sorafenib is a kinase inhibitor used to treat primary kidney cancer (renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), FLT3-ITD positive AML, and radioactive iodine resistant advanced thyroid cancer. Sorafenib can be taken by mouth.

Stable isotope labeled [13CD3]-Sorafenib is intended for use as an internal standard for the quantification of Sorafenib by LC or GC-mass spectrometry.

Aspect
Solid
Purity
Chemical purity 95%; Isotopic Enrichment 98%
Solubility
DMSO, DMF, MeOH, EtOH
Molecular weight
468.84
Molecular formula

C2013CH13D3ClF3N4O3

IUPAC
4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N-(methyl-13C-d3)picolinamide

J. E. Adaway, B. G. Keevil, J. Chromatogr. B, 2012, 883-884, 33-49. (read article)

Purchase [13CD3]-Sorafenib

Get a quote on this product

We're ready to solve any rare chemicals sourcing or molecular design problem... Give us a shout! Please fill out this form completely.

If you don't find a product in our current offer, please don't hesitate to request a quote using our contact form.

Add to my selection

Related products

Macimorelin acetate
CAS #
945212-59-9
Details
Ribociclib
CAS #
1211441-98-3
Details
[13C6]-Glucosylsphingosine ([13C6]-GlSph...
CAS #
299172-48-8
Details
See more products

logo footerNucleosyn

111 Bd Duhamel du Monceau

45160 Olivet

Products

See Catalog

Know more about products

Contact

Contact Form

+33 2 38 49 45 73

Follow us

Other Infos

Legal notices

Privacy Policy & cookies infos

General terms & conditions

© Nucleosyn 2025 - All rights reserved

Design and development Think Ad Communication